**CANADIAN GASTROENTEROLOGY ELSEWHERE**

## Vasopressin antagonists and dilutional hyponatremia

D Mohamed Babatin MD, Samuel S Lee MD FRCPC

### ARTICLE


“The more he drinks, the thirstier he grows”

– Ovid, Fasti

### COMMENTARY

The paradox of dilutional hyponatremia, as described by Ovid two millennia ago, continues to apply to patients with advanced cirrhosis today: they have unrelenting thirst despite vastly increased total body water. Hyponatremia of less than 130 mmol/L occurs in 30% of cirrhotic patients (1), and is mainly due to the reduced capacity of their kidneys to excrete free water.

Several factors may contribute to the development of dilutional hyponatremia in cirrhosis: decreased glomerular filtration rate and, thus, reduced delivery of filtrate to the descending loop of Henle; reduced renal prostaglandin synthesis; and, most importantly, increased nonosmotic secretion of antidiuretic hormone (vasopressin) (2). Vasopressin is synthesized in the neurons of the supraoptic and paraventricular nuclei and released by the neurohypophysis into the systemic circulation. In normal individuals, vasopressin release is suppressed by low plasma osmolality. This feedback regulation is absent in patients with decompensated cirrhosis (2,3); in other patients, vasopressin secretion is increased further by hyponatremia (2,3) and by a decrease in urinary osmolality. No dose-related increase in free water clearance, serum sodium, and hematocrit occurred in patients with hyponatremia or in those with ascites but normal serum electrolyte profiles. This can be accomplished by either reducing hypothalamic vasopressin production or by blocking renal V2 receptors. Opioid agonists of the κ-subtype can reduce hypothalamic vasopressin secretion (6) but are of limited use because of their numerous other central nervous system effects, especially impaired mentation.

Vasopressin receptors, drugs like VPA-985 antagonize the effect of vasopressin. Aquaporin-2 density increases in cirrhotic rats. Administration of a vasopressin antagonist, however, abolishes aquaporin-2 expression (5).

The traditional management of dilutional hyponatremia is water restriction. However, given the intense thirst, attempts to limit daily water intake to 1000 to 1500 mL are usually ineffective in the outpatient setting. Moreover, severe water restriction can induce dehydration, further decreasing glomerular filtration rate and renal function, especially in patients with renal impairment or the hepatorenal syndrome.

Accordingly, recent research has examined vasopressin antagonism as a means of increasing free water excretion and thus improving the serum electrolyte profiles. This can be accomplished by either reducing hypothalamic vasopressin production or by blocking renal V2 receptors. Opioid agonists of the κ-subtype can reduce hypothalamic vasopressin secretion (6) but are of limited use because of their numerous other central nervous system effects, especially impaired mentation.

This leaves the approach of blocking peripheral V2 receptors in the kidney. Several nonpeptide, orally active V2 receptor antagonists have been synthesized, of which VPA-985 is the most studied in clinical trials. Prior to the study of Wong and colleagues, the only other clinical study was a small pharmacodynamic dose-finding study in cirrhotic patients with ascites but normal serum electrolytes (7).

The Wong study is important because it was the first phase II study to specifically examine the effects of a V2 antagonist on hyponatremia. This multicenter, randomized, double-blind, placebo-controlled trial involved a total of 44 patients: 33 had cirrhosis, six had congestive heart failure and five had syndrome of inappropriate antidiuretic hormone secretion (8). The patients received various doses of VPA-985 (25 mg twice daily, 125 mg twice daily or 250 mg twice daily) or placebo for a seven-day period, or until correction of hyponatremia. To a certain extent, the eligibility criteria were constructed to reflect clinical practice. For example, patients were allowed to remain on diuretics. Some of the patients had renal impairment; the maximum allowable serum creatinine was 265 μmol/L or less in patients without cirrhosis and 176 μmol/L or less in cirrhotics.

The investigators found that VPA-985 produced a significantly greater aquaretic response than placebo (8). There was a dose-related increase in free water clearance, serum sodium and serum osmolality, and a decrease in urinary osmolality. No
change in urine sodium excretion was observed. Adverse
effects were relatively few, especially at the lower doses. No
orthostatic hypotension or change in serum creatinine levels
was observed. However, at the highest dosage, patients reported
increased thirst, and there were some overt and subtle signs of
mild dehydration. Moreover, even in this relatively short-term
study, there was evidence of tachyphylaxis. The aquaretic
effects appeared to plateau by day 5, and plasma vasopressin
levels continued to rise. Although V2 receptor density was not
evaluated in this clinical study, the authors speculated that
high vasopressin levels induced the expected receptor down-
regulation. A similar renal V2-receptor downregulation has
been previously noted with high vasopressin levels in dehydra-
tion (9). Therefore, the long-term efficacy of these drugs
remains unclear.

Further studies obviously need to be done with chronic admin-
istration of vasopressin antagonists, and the optimum dosage
schedules for various degrees of renal and cardiac dysfunction
need to be determined. Moreover, it would be very interesting
to see if avidly thirsty patients could eventually drink enough
water to overcome the effects of long-term vasopressin antago-
nism, and ‘reset’ the serum sodium again at a low level.

In conclusion, treatment of cirrhotic patients with dilutional
hyponatremia would be significantly improved by vasopressin
receptor antagonists like VPA-985, which improve serum elec-
trolyte levels by increasing renal free water excretion. We are
not yet ready to start using these drugs routinely, but this study
of Wong and her colleagues is an important first step.

D Mohamed Babatin MD
Samuel S Lee MD FRCP
University of Calgary Liver Unit
Calgary, Alberta

REFERENCES
1. Arroyo V, Rodes J, Gutierrez-Lizaraga MA, Revert L. Prognostic
value of spontaneous hyponatremia in cirrhosis with ascites. Am J
3. Bichet D, Szatalowicz V, Chaimovitz C, Schrier RW. Role of
vasopressin in abnormal water excretion in cirrhotic patients.
4. Knepper MA. Molecular physiology of urinary concentrating
mechanisms: Regulation of aquaporin water channels by vasopressin.
AQP-CD in water retention in SIADH and cirrhotic rats. Am J
6. Lutz-Bucher B, Koch B. Evidence for a direct inhibitory effect of
morphine on the secretion of posterior pituitary hormones. Eur J
effects of a nonpeptide antidiuretic hormone V2 antagonist in
8. Wong F, Blei AT, Blends L, Thuluvath P. A vasopressin receptor
antagonist (VPA-985) improves serum sodium concentration in
patients with hyponatremia: A multicenter, randomized, placebo-
9. Steiner M, Phillips ML. Renal tubular vasopressin receptors
cirrhosis with a vasopressin receptor antagonist: A randomized